Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Ovarian Neoplasms 7 Uterine Cervical Neoplasms 2 Rectal Neoplasms 2 Endometrial Neoplasms 2 Uveal Melanoma 1 Sarcoma, Alveolar Soft Part 1 Sarcoma 1 Pleural Effusion, Malignant 1 Neoplasms 1 Neoplasm Metastasis 1 Lung Neoplasms 1 Leiomyosarcoma 1 Gliosarcoma 1 Glioblastoma 1 Fallopian Tube Neoplasms 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinosarcoma 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Brain Neoplasms 1 Biliary Tract Neoplasms 1

Interventions

Gemcitabine 58 Cisplatin 41 Capecitabine 27 Oxaliplatin 25 durvalumab 16 Fluorouracil 16 Leucovorin 15 S 1 (combination) 11 lenvatinib 10 Nivolumab 10 Irinotecan 10 pembrolizumab 8 apatinib 8 Immune Checkpoint Inhibitors 7 130-nm albumin-bound paclitaxel 7 tremelimumab 6 Bevacizumab 6 camrelizumab 5 Trastuzumab 5 Drug Therapy 5 Blood Specimen Collection 5 Albumin-Bound Paclitaxel 5 tislelizumab 4 irinotecan sucrosofate 4 Taxes 4 Liquid Biopsy 4 Folfox protocol 4 toripalimab 3 surufatinib 3 gemcitabine-oxaliplatin regimen 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Biliary Tract Neoplasms × cediranib × Clear all

NCT00939848 2014-10-27

ABC-03

University College, London

Phase 2/3 Completed

Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡